Company GlycoMimetics, Inc.

Equities

GLYC

US38000Q1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
2.8 USD +9.38% Intraday chart for GlycoMimetics, Inc. +9.38% +18.64%

Business Summary

GlycoMimetics, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of glycomimetic drugs. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer, and infection. Its drug candidates include Uproleselan, GMI-1359, GMI-1687, and Galectin Antagonists. It is developing Uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). Its GMI-1359 targets both E-selectin and a chemokine receptor known as CXCR4. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. The Company is engaged in advancing other preclinical-stage programs, including small-molecule glycomimetic compounds that inhibit the protein galectin-3.

Number of employees: 39

Sales per Business

USD in Million2021Weight2022Weight Delta
Glycomimetic Compounds
100.0 %
1 100.0 % 0 100.0 % -93.53%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
1 100.0 % 0 100.0 % -93.53%

Managers

Managers TitleAgeSince
Chief Executive Officer 52 21-08-05
Founder 64 03-04-03
Director of Finance/CFO 49 10-01-31
Chief Tech/Sci/R&D Officer 63 22-09-05
Chief Tech/Sci/R&D Officer - 22-03-01
Corporate Officer/Principal 48 -
Corporate Officer/Principal 56 22-02-22
General Counsel - 19-04-28
Comptroller/Controller/Auditor 53 13-12-31
General Counsel - 21-11-21

Members of the board

Members of the board TitleAgeSince
Director/Board Member 71 16-03-16
Director/Board Member 66 17-06-11
Director/Board Member 59 18-11-27
Founder 64 03-04-03
Director/Board Member 71 17-03-12
Chairman 56 14-03-30
Director/Board Member 69 14-07-09
Chief Executive Officer 52 21-08-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 64,393,294 62,467,995 ( 97.01 %) 0 97.01 %

Shareholders

NameEquities%Valuation
BVF, Inc.
14.82 %
9,544,262 14.82 % 28 M $
Artal Group SA
13.34 %
8,589,064 13.34 % 25 M $
NEA Management Co. LLC
6.224 %
4,007,977 6.224 % 12 M $
Octagon Capital Advisors LP
4.659 %
3,000,000 4.659 % 9 M $
Vanguard Global Advisers LLC
3.761 %
2,421,869 3.761 % 7 M $
AXA Investment Managers UK Ltd.
2.465 %
1,587,298 2.465 % 5 M $
Goldman Sachs & Co. LLC
1.428 %
919,355 1.428 % 3 M $
BlackRock Institutional Trust Co. NA
1.116 %
718,329 1.116 % 2 M $
657,502 1.021 % 2 M $
Acadian Asset Management LLC
0.8404 %
541,176 0.8404 % 2 M $

Company contact information

GlycoMimetics, Inc.

9708 Medical Center Drive

20850, Rockville

+240 243 1201

http://www.glycomimetics.com
address GlycoMimetics, Inc.(GLYC)